- patients who may be included in more than one of the sub-cohorts - other vaccination received in the 15 days preceding recruitment or planned in the month following the second vaccine injection - known or suspected allergy to one of the components of the vaccine - severe reaction after previous administration of any influenza vaccine (multiple sclerosis, guillain-barré syndrome) - contact subjects of a patient with an undetected documented sars-cov-2 infection - evocative signs of covid-19 - history of documented sars-cov-2 infection of less than 3 months (rt-pcr, lamp pcr, antigen test) - last outbreak of the disease less than 3 months old for patients with multiple sclerosis; less than a month old for patients with autoimmune or autoinflammatory diseases - for patients with hiv, transient viremia (blip) less than 3 months old - intercurrent infection - for organ transplants, episode of cellular or humoral rejection during the 3 months preceding inclusion - healthy volunteers - pregnancy less than 13 weeks old according to the declaration of pregnancy - refusal of participation by the patient - patients subject to legal protection measures

- patients who may be included in more than one of the sub-cohorts - other vaccination received in the 15 days preceding recruitment or planned in the month following the second vaccine injection - known or suspected allergy to one of the components of the vaccine - severe reaction after previous administration of any influenza vaccine (multiple sclerosis, guillain-barré syndrome) - contact subjects of a patient with an undetected documented sars-cov-2 infection - evocative signs of covid-19 - history of documented sars-cov-2 infection of less than 3 months (rt-pcr, lamp pcr, antigen test) - last outbreak of the disease less than 3 months old for patients with multiple sclerosis; less than a month old for patients with autoimmune or autoinflammatory diseases - for patients with hiv, transient viremia (blip) less than 3 months old - intercurrent infection - for organ transplants, episode of cellular or humoral rejection during the 3 months preceding inclusion - healthy volunteers - pregnancy less than 13 weeks old according to the declaration of pregnancy - refusal of participation by the patient - patients subject to legal protection measures

- patients who may be included in more than one of the sub-cohorts - other vaccination received in the 15 days preceding recruitment or planned in the month following the second vaccine injection - known or suspected allergy to one of the components of the vaccine - severe allergic site (history of anaphylactic shock) - severe reaction after previous administration of any influenza vaccine (multiple sclerosis, guillain-barré syndrome) - contact subjects of a patient with an undetected documented sars-cov-2 infection - evocative signs of covid-19 - history of documented sars-cov-2 infection of less than 3 months (rt-pcr, lamp pcr, antigen test) - last outbreak of the disease less than 3 months old - intercurrent infection - for organ transplants, episode of cellular or humoral rejection during the 3 months preceding inclusion - healthy volunteers - pregnancy in progress or planned within 3 months after vaccination - refusal of participation by the patient - patients subject to legal protection measures

- patients who may be included in more than one of the sub-cohorts - other vaccination received in the 15 days preceding recruitment or planned in the month following the second vaccine injection - known or suspected allergy to one of the components of the vaccine - severe allergic site (history of anaphylactic shock) - severe reaction after previous administration of any influenza vaccine (multiple sclerosis, guillain-barré syndrome) - contact subjects of a patient with an undetected documented sars-cov-2 infection - evocative signs of covid-19 - history of documented sars-cov-2 infection of less than 3 months (rt-pcr, lamp pcr, antigen test) - last outbreak of the disease less than 3 months old - intercurrent infection - for organ transplants, episode of cellular or humoral rejection during the 3 months preceding inclusion - healthy volunteers - pregnancy in progress or planned within 3 months after vaccination - refusal of participation by the patient - patients subject to legal protection measures